Brilinta ticagrelor regulatory update

AstraZeneca said the American Heart Association (AHA) and American College of Cardiology (ACC) updated treatment guidelines and now prefer the use of the pharma's Brilinta ticagrelor over clopidogrel to manage non-ST-elevation acute coronary syndrome (ACS) in patients who undergo an early invasive or ischemia-guided strategy or those who receive a coronary stent. AZ said this is the first time the AHA and ACC recommended a purinergic receptor P2Y G protein-coupled 12 ( P2RY12; P2Y12) antagonist over another to treat ACS. The pharma markets Brilinta in the U.S. to reduce the rate of thrombotic cardiovascular events in ACS patients. AZ markets the product in the EU as Brilique to prevent atherothrombotic events in ACS patients. The Medicines Co. co-promotes Brilinta in the U.S. (see BioCentury, Nov. 11, 2013). ...